![]() |
CrossRef Text and Data Mining |
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
Serum Testosterone Level as Possible Predictive Marker for Prognosis in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide |
Dong Hyeon An, Hwiwoo Kim, Donghyun Lee, In Gab Jeong, Dalsan You, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn |
Korean J Urol Oncol. 2021;19(1):60-69. Published online 2021 February 26 DOI: https://doi.org/10.22465/kjuo.2021.19.1.60 |
Serum Testosterone Level as Possible Predictive Marker for Prognosis in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide Enzalutamide for patients with metastatic castration-resistant prostate cancer Enzalutamide in Metastatic Castration Resistant Prostate Cancer 232P Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experience Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: A retrospective study Cost-Utility Analysis of Enzalutamide for Patients with Previously Treated Metastatic Castration-Resistant Prostate Cancer (MCRPC) Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate Higher serum testosterone levels predict poor prognosis in castration‐resistant prostate cancer patients treated with docetaxel 344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641) Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer |